A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in participants with established atherosclerotic CV disease (ASCVD) treated with SOC, according to local clinical practice.
- EligibilityCriteria: Inclusion Criteria:  Adult participants ≥ 18 years of age. Participants or participant's legally authorized representative has provided informed consent to participate in this study. Participants who meet one of the following: Prescribed Repatha® in addition to an existing SOC treatment according to local guidelines and approved label.  OR  Already received SOC treatment prior to enrollment. Participants with ANY of the following. Diagnosis of MI OR stroke within 2 years before enrollment. 2 MIs OR ≥ 2 strokes OR (≥ 1 MI AND ≥ 1 stroke) any time before enrollment. Diagnosis of (MI OR stroke) AND diabetes. Diagnosis of (MI OR stroke) AND documented multivessel disease (defined as > 50% stenosis of ≥ 2 major coronary arteries on coronary angiography or coronary artery contrast enhanced computed tomography). Diagnosis of symptomatic peripheral arterial disease. Most recent fasting LDL-C ≥ 70 mg/dL (≥ 1.8 mmol/L) or nonhigh-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (≥ 2.6 mmol/L) within 6 months prior to enrollment. Most recent fasting triglycerides ≤ 400 mg/dL (≤ 4.5 mmol/L) within 6 months prior to enrollment.  Exclusion Criteria:  Stroke within past 1 month. Known hemorrhagic stroke at any time. Stroke due to thromboembolic event. Any prior use of Repatha® or other proprotein convertase subtilisin/kexin type 9 inhibition treatments within past 6 months prior to enrollment. Participants currently enrolled in another study involving any investigational procedure, device or drug. Participants prescribed Repatha® with a history of severe hypersensitivity or allergy to any subsidiary. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 150 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The study population comprises Chinese participants with established ASCVD treated with Repatha® in combination with SOC or with SOC alone in a clinical setting which includes any primary through tertiary healthcare setting where Repatha® is prescribed. - SamplingMethod: Non-Probability Sample